Pediatric Deep Brain Stimulation for Drug-Resistant Epilepsy: What a Review Found

What was studied

Researchers combined results from 19 studies involving 149 children with drug-resistant epilepsy who received deep brain stimulation (DBS). Patients were assessed after at least 12 months of follow-up.

The review examined seizure reduction, seizure freedom, adverse events, whether age was associated with response, and whether outcomes differed by the area of the brain being stimulated.

What they found

An estimated 63.3% of patients had their seizure frequency reduced by at least half, and 13.8% were seizure-free at 12 months or later. Age at implantation was not associated with treatment response in the analysis.

Response rates ranged from 46.2% to 76.8% across the brain targets studied, but the differences between targets were not statistically significant. Across 17 studies reporting safety outcomes, the pooled rates were 16.5% for overall adverse events, 10.8% for major events, and 12.5% for minor events. The abstract does not clarify how these categories relate to one another. No procedure-related deaths were reported.

Limits of the evidence

The review included 149 patients across 19 studies, and evidence about long-term efficacy and safety remains limited. The abstract does not describe the individual study designs, comparison groups, epilepsy types, DBS settings, or definitions of major and minor adverse events. Patients were followed for at least 12 months, but outcomes over longer periods remain uncertain.

Differences in response rates by brain target were not statistically significant and may reflect chance or differences among patients and studies. The lack of an observed association with age does not establish that age has no influence on outcomes. Similarly, no reported procedure-related deaths does not mean that the procedure has no risk.

For families and caregivers

The findings suggest that DBS may reduce seizures by at least half for some children whose epilepsy has not responded to medicines, while complete seizure freedom was less common. Adverse events were also reported. These results support DBS as an emerging treatment option but do not establish which children or stimulation targets are most likely to benefit.

What to watch next

Larger prospective multicenter studies with consistent safety reporting and longer follow-up are needed to clarify who is most likely to benefit, identify the best stimulation targets, and better assess long-term outcomes.

Terms in this summary

Drug-resistant epilepsy

Epilepsy that continues to cause seizures despite trials of anti-seizure medicines.

Deep brain stimulation (DBS)

A treatment in which implanted electrodes deliver electrical stimulation to selected areas deep in the brain.

Responder rate

The percentage of patients whose seizure frequency fell by at least 50%.

Seizure freedom

Having no seizures, as reported at the study's follow-up assessment.

Target nucleus

The specific brain area where DBS stimulation is delivered.

Meta-analysis

A statistical method that combines results from multiple studies.

95% confidence interval

A range that reflects uncertainty around an estimated result; narrower ranges generally indicate greater precision.

Adverse event

An unwanted medical problem reported during or after treatment, whether or not the treatment was established as its cause.